Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Xiang Qing Yu"'
Autor:
Patricia LoRusso, Jennifer McDevitt, Jaye Viner, Jaiqi Huang, Patricia Burke, Xiang-Qing Yu, Li Shi, Theresa LaVallee, Donald Northfelt, Jonathan Rosenberg, Elizabeth R. Plimack, Michael Menefee, Paul Haluska
Purpose: This phase I, multicenter, open-label, single-arm, dose-escalation, and dose-expansion study evaluated the safety, tolerability, and antitumor activity of MEDI-573 in adults with advanced solid tumors refractory to standard therapy or for wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ecef3674d52f0b288a0c020bd531566
https://doi.org/10.1158/1078-0432.c.6523185
https://doi.org/10.1158/1078-0432.c.6523185
Autor:
Patricia LoRusso, Jennifer McDevitt, Jaye Viner, Jaiqi Huang, Patricia Burke, Xiang-Qing Yu, Li Shi, Theresa LaVallee, Donald Northfelt, Jonathan Rosenberg, Elizabeth R. Plimack, Michael Menefee, Paul Haluska
Figure S1. Top: mRNA differential expression of individual proliferation genes (AURKA, CCNB1, MKI67, and MYBL2) and cancer invasion genes (CTSL2 and MMP11) and the bladder cancer marker, UPK3A, in biopsy samples (from patients with bladder cancer at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71b880161c23ebcaf2ca21815bb9fab8
https://doi.org/10.1158/1078-0432.22456008
https://doi.org/10.1158/1078-0432.22456008
Autor:
Lu Shan, Magali Colazet, Kim L Rosenthal, Xiang-Qing Yu, Jared S Bee, Andrew Ferguson, Melissa M Damschroder, Herren Wu, William F Dall'Acqua, Ping Tsui, Vaheh Oganesyan
Publikováno v:
PLoS ONE, Vol 11, Iss 8, p e0160345 (2016)
The immunoglobulin Fc region is a homodimer consisted of two sets of CH2 and CH3 domains and has been exploited to generate two-arm protein fusions with high expression yields, simplified purification processes and extended serum half-life. However,
Externí odkaz:
https://doaj.org/article/91d568f9c0f24ee8beba1b700261d04c
Autor:
Yuan, Fang, Qin, Xuan, Zhou, Dan, Xiang, Qing-Yu, Wang, Min-Ting, Zhang, Zhi-Rong, Huang, Yuan
Publikováno v:
In European Journal of Pharmaceutics and Biopharmaceutics 2008 70(3):770-776
Autor:
Robert E. Hollingsworth, Adeela Kamal, Haihong Zhong, Ryan Fleming, Nazzareno Dimasi, Herren Wu, Mary Jane Hinrichs, Xiang-Qing Yu, Pamela Thompson, Robert M. Woods, Patrick Strout, Song Cho, Cui Chen, Molly Reed, Rakesh Dixit, Binyam Bezabeh, Fengying Huang, Jay Harper, Xizhe Gao, Shenlan Mao, Changshou Gao
Publikováno v:
Journal of Controlled Release. 236:100-116
Antibody-drug conjugates (ADCs) are among the most promising empowered biologics for cancer treatment. ADCs are commonly prepared by chemical conjugation of small molecule cytotoxic anti-cancer drugs to antibodies through either lysine side chains or
Publikováno v:
British Journal of Clinical Pharmacology. 81:918-928
Aims Sifalimumab, a human immunoglobulin (Ig) G1 monoclonal antibody against INF-alpha, is being studied as a treatment for systemic lupus erythematosus (SLE). This analysis characterized population pharmacokinetics (PK) of sifalimumab following repe
Autor:
M. Jack Borrok, Xiang-Qing Yu, Ping Tsui, Vaheh Oganesyan, Yanli Wu, William Dall'acqua, Nurten Beyaz
Publikováno v:
Journal of Biological Chemistry. 290:4282-4290
The Fc domain of IgG has been the target of multiple mutational studies aimed at altering the pH-dependent IgG/FcRn interaction to modulate IgG pharmacokinetics. These studies have yielded antibody variants with disparate pharmacokinetic characterist
Autor:
Arnaud C. Tiberghien, Howard Phillip Wilson, Xiang Qing Yu, Binyam Bezabeh, Michele Gunsior, Molly Reed, Mary Jane Hinrichs, Jay Harper, Rakesh Dixit, Luke Masterson, Patricia C. Ryan, Kapil Vashisht, Shameen Afif-Rider, Marlon Rebelatto, Bo Zheng, Neki V. Patel, Haihong Zhong, Nazzareno Dimasi, Cui Chen, Shannon Breen, Pauline M. Ryan
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(19)
Purpose: To use preclinical models to identify a dosing schedule that improves tolerability of highly potent pyrrolobenzodiazepine dimers (PBDs) antibody drug conjugates (ADCs) without compromising antitumor activity.Experimental Design: A series of
Autor:
William Dall'acqua, Xiang-Qing Yu, Adem C. Koksal, Romana Cvitkovic, C. Kendall Stover, Jessica Bonnell, Yan Chen, Qun Wang, Xizhe Gao, Xiaodong Xiao, Chien-Ying Chang, Ellen O'Connor, Mark Pelletier, Herren Wu
Publikováno v:
mAbs. 9(3)
Antibodies carry out a plethora of functions through their crystallizable fragment (Fc) regions, which can be naturally tuned by the adoption of several isotypes and post-translational modifications. Protein engineering enables further Fc function mo
Autor:
Xiang-Qing Yu, Gabriel Robbie, Howard I. Schwartz, Terramika Bellamy, Kathryn M Jensen, Martha Hernandez-Illas, Yuling Wu, Hasan S. Jafri, Mark T. Esser
Publikováno v:
Antimicrobial Agents and Chemotherapy
MEDI4893 is an investigational immunoglobulin G1(κ) monoclonal antibody that specifically binds to and neutralizes alpha-toxin, a key Staphylococcus aureus virulence factor. A triple-amino-acid substitution, M252Y/S254T/T256E, was engineered into th